CancerDrs Find care

Endometrial Cancer clinical trials

188 actively recruiting endometrial cancer trials in the United States. The most common gynecologic cancer in the U.S. Trials focus on hormonally driven subtypes, MSI-H/dMMR immunotherapy, and advanced disease.

Data from ClinicalTrials.gov · last refreshed · Endometrial Cancer stats on SEER

49
Phase 1
73
Phase 2
14
Phase 3
52
Other

Endometrial Cancer by the numbers (U.S.)

69,120
Estimated new cases (2025)
13,860
Estimated deaths (2025)
81.1%
5-year relative survival
64
Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Browse endometrial cancer trials by state

Texas 106 California 84 New York 83 Florida 80 Ohio 62 Virginia 61 Massachusetts 60 Michigan 56 Pennsylvania 54 Illinois 48 Tennessee 44 Minnesota 43 Missouri 39 New Jersey 39 North Carolina 36 Oklahoma 36 Georgia 33 Washington 33 Maryland 32 Oregon 32 Colorado 31 Wisconsin 31 Utah 28 Arizona 27 Connecticut 26 Indiana 26 Alabama 22 Louisiana 21 Rhode Island 18 Arkansas 16 Kentucky 16 Nevada 14 New Mexico 14 Iowa 13 Nebraska 13 South Dakota 13 South Carolina 12 District of Columbia 10 Maine 9 Montana 9 North Dakota 9 Kansas 8 Alaska 6 Delaware 6 Hawaii 6 Idaho 6 Mississippi 6 West Virginia 6 Vermont 4 New Hampshire 1

Top trials by phase + site coverage

Phase 3 Recruiting NIH

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrin…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05256225
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • Alaska Women's Cancer Care — Anchorage, Alaska
  • Banner University Medical Center - Tucson — Tucson, Arizona

+ 401 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizumab in treating patients with stage III, …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07198074
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • Mercy Cancer Center - Carmichael — Carmichael, California
  • Mercy San Juan Medical Center — Carmichael, California

+ 105 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response …

Sponsor: Karyopharm Therapeutics Inc
NCT ID: NCT05611931
Locations:
  • The University of Alabama at Birmingham — Birmingham, Alabama
  • Honor Health — Phoenix, Arizona
  • University of Arkansas for Medical Sciences — Little Rock, Arkansas

+ 81 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 s…

Sponsor: AstraZeneca
NCT ID: NCT07044336
Locations:
  • Research Site — Tucson, Arizona
  • Research Site — La Jolla, California
  • Research Site — Los Angeles, California

+ 60 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progress…

Sponsor: AstraZeneca
NCT ID: NCT06989112
Locations:
  • Research Site — Tucson, Arizona
  • Research Site — Little Rock, Arkansas
  • Research Site — Duarte, California

+ 57 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer

This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Stand…

Sponsor: NRG Oncology
NCT ID: NCT05646316
Locations:
  • George Washington University Medical Center — Washington D.C., District of Columbia
  • UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida

+ 52 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicate…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06952504
Locations:
  • University of South Alabama, Mitchell Cancer Institute ( Site 6033) — Mobile, Alabama
  • Alaska Women's Cancer Care ( Site 6036) — Anchorage, Alaska
  • University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 6020) — Orange, California

+ 41 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are considered standard medical care for the treatment of recurrent or progressive endomet…

Sponsor: Genmab
NCT ID: NCT07166094
Locations:
  • SMH - Sarasota - Main Campus — Sarasota, Florida
  • Emory Winship Cancer Inst. — Atlanta, Georgia
  • Emory Winship Cancer Inst. — Atlanta, Georgia

+ 32 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part…

Sponsor: Kartos Therapeutics, Inc.
NCT ID: NCT05797831
Locations:
  • Kaiser Permanente Center — Vallejo, California
  • Northside Hospital — Atlanta, Georgia
  • St. Joseph — Savannah, Georgia

+ 16 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer

This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachytherapy in treating participants with stage I-II endometrial cancer. Short course va…

Sponsor: University of Utah
NCT ID: NCT03422198
Locations:
  • Stanford Cancer Center — Palo Alto, California
  • Loyola University Medical Center — Maywood, Illinois
  • MD Anderson — Houston, Texas

+ 2 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

The study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample. In Cohort 1, the main goal is to assess how…

Sponsor: BioNTech SE
NCT ID: NCT06340568
Locations:
  • MedStar Washington Hospital Center — Washington D.C., District of Columbia
  • Broward Health Medical Center — Fort Lauderdale, Florida
  • The Center of Hope Reno — Reno, Nevada

+ 1 more site in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.

Sponsor: Daiichi Sankyo
NCT ID: NCT07022483
Locations:
  • Mount Sinai Medical Center — Miami Beach, Florida
  • Trials365 LLC — Shreveport, Louisiana
  • Avera Medical Group Gynecologic Oncology Sioux Falls — Sioux Falls, South Dakota
View on ClinicalTrials.gov →

Showing 12 of 188 trials. See all on ClinicalTrials.gov

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20